Shanghai Henlius Biotech Receives Regulatory Approval for Phase 1 Clinical Trial of HLX97, a First-in-Class KAT6A/B Inhibitor

Key Highlights

• Regulatory Milestone: Shanghai Henlius Biotech, Inc. has obtained approval from the National Medical Products Administration (NMPA) for its Investigational New Drug (IND) application to initiate a Phase 1 clinical trial of HLX97, a KAT6A/B small molecule inhibitor, for advanced or metastatic solid tumours.
• First-in-Class Opportunity: As of the announcement date, no KAT6A/B small molecule inhibitor has been approved for marketing globally, positioning HLX97 as a potential first-in-class therapeutic agent.
• Targeting Unmet Needs in Oncology: HLX97 is specifically designed to target lysine acetyltransferase 6A/B (KAT6A/B), enzymes involved in tumourigenesis and therapy resistance, particularly in breast cancer.
• Potential for Overcoming Therapy Resistance: Amplification or overexpression of KAT6A is closely linked with resistance to endocrine therapy in breast cancer. HLX97’s mechanism of action offers promise in overcoming this resistance.
• Positive Preclinical Data: Non-clinical studies have demonstrated that HLX97 can effectively inhibit KAT6A/B activity, showing both anti-tumour effects and good safety profiles.
• Board Endorsement: The announcement is made with the full endorsement of the board led by Chairman Wenjie Zhang.

Detailed Analysis for Investors

Shanghai Henlius Biotech’s recent announcement marks a significant step forward in the company’s oncology pipeline. The Phase 1 IND approval for HLX97 represents a critical regulatory milestone, as it allows the company to commence human clinical trials for a drug class with no approved competitors worldwide.

KAT6A and KAT6B are histone lysine acetyltransferases that play a fundamental role in the acetylation of lysine residues on histone H3 and other chromatin-associated proteins. The carcinogenic potential of KAT6A/B in various tumour types, especially in breast cancer, is well documented. Importantly, the overexpression of KAT6A is associated with the development of resistance to endocrine therapy—a major challenge in the management of advanced breast cancer. HLX97’s ability to inhibit KAT6A/B may provide a novel solution for patients who have developed resistance to current therapies.

In preclinical models, HLX97 has shown the ability to inhibit the activity of KAT6A/B, demonstrating promising anti-tumour efficacy as well as a favourable safety profile. If these results are replicated in clinical studies, HLX97 could become a breakthrough therapy for patients with advanced or metastatic solid tumours, including those with endocrine-resistant breast cancer.

Potential Price-Sensitive Information for Shareholders

• First Approval Globally: The lack of any approved KAT6A/B inhibitor globally presents a unique opportunity for Shanghai Henlius Biotech to capture a first-mover advantage in a potentially lucrative market segment.
• Pipeline Progress: Regulatory approval to commence human trials is a de-risking event in drug development and may positively impact investor sentiment and the company’s valuation.
• Uncertainty Remains: The company has cautioned that there is no guarantee of successful development or commercialization of HLX97, a reminder of the inherent risks in clinical drug development.

Corporate Governance Update

The announcement was issued by Chairman Wenjie Zhang on behalf of the board of directors, which includes a mix of executive, non-executive, and independent non-executive directors, reflecting a robust governance structure supporting the company’s strategic initiatives.

Conclusion

The IND approval for HLX97 marks a promising advance for Shanghai Henlius Biotech in the field of oncology, with potential to address significant unmet medical needs. This development is likely to garner attention from investors, as it could pave the way for value creation through clinical advancement and eventual commercialization—if successful. However, shareholders should remain aware of the risks associated with early-stage clinical development.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The development and commercialization of HLX97 are subject to clinical risk and regulatory review. Investors are advised to exercise caution and perform their own due diligence before making any investment decisions related to Shanghai Henlius Biotech, Inc.

View HENLIUS Historical chart here